Case report: a transcatheter aortic valve replacement failure secondary to COVID-19 infection

• Published in: European heart journal. Case reports Vol. 7; no. 2; p. ytad054
• Main Authors: Tacon, P Ryan, Cao, Louie, Birkeland, Kade, Kedan, Ilan
• Format: Report
• Language: English
• Published: 01-02-2023
• ISSN: 2514-2119
• DOI: 10.1093/ehjcr/ytad054

BackgroundValve thrombosis is a well-documented cause of bioprosthetic valve failure. Case reports have been published of prosthetic valve thrombosis secondary to COVID-19 infection. This is the first case report of COVID-19 associated valve thrombosis in a patient with transcatheter aortic valve replacement (TAVR). Case summaryA 90-year-old female with atrial fibrillation on therapeutic apixaban and status-post TAVR presented with COVID-19 infection and was found to have severe bioprosthetic valvular regurgitation with features suggestive of valve thrombosis. She underwent valve-in-valve TAVR with resolution of valvular dysfunction. DiscussionThis case report contributes to a growing body of evidence describing the occurrence of thrombotic complications in patients with valve replacement and COVID-19 infection. Increased vigilance and continued investigation are warranted to better characterize thrombotic risk and to inform optimal antithrombotic strategies during COVID-19 infection.